Clinical Trials Logo

Adnexal Carcinoma clinical trials

View clinical trials related to Adnexal Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05859074 Recruiting - Melanoma Clinical Trials

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Start date: May 4, 2023
Phase: Phase 1
Study type: Interventional

Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participants' cancer. The purpose of this study if to find the highest dose of MQ710 that causes few or mild side effects in participants with a solid tumor cancer diagnosis.

NCT ID: NCT05842629 Recruiting - Ovarian Cancer Clinical Trials

Improved Diagnosis of Ovarian Cancer

Start date: May 15, 2021
Phase:
Study type: Observational

After implementation of systematic image description of adnexal masses, we aim to improve and evaluate our use of available imaging methods and biomarkers for classifying adnexal masses and distinguishing between benign and malignant adnexal masses in the hands of clinicians in Central Denmark Region. Secondarily, we want to improve our management of adnexal masses by evaluating the complications and longitudinal changes in conservatively managed adnexal masses. Data is registered prospectively but analyzed retrospectively.

NCT ID: NCT02978625 Active, not recruiting - Clinical trials for Merkel Cell Carcinoma

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Start date: September 27, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other places in the body (advanced) or do not responded to treatment. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and nivolumab may work better compared to usual treatments in treating patients with lymphomas or non-melanoma skin cancers.